UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 12b-25

 

Commission File Number 000-55575

 

NOTIFICATION OF LATE FILING

 

(Check One): [X] Form 10-K [  ] Form 20-F [  ] Form 11-K [  ] Form 10-Q [  ] Form N-SAR [  ] Form N-CSR

 

For Period Ended: December 31, 2020

 

[  ] Transition Report on Form 10-K
[  ] Transition Report on Form 20-F
[  ] Transition Report on Form 11-K
[  ] Transition Report on Form 10-Q
[  ] Transition Report on Form N-SAR

 

For Transition Period Ended: __________________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I - REGISTRANT INFORMATION

 

Full Name of Registrant: Sigyn Therapeutics, Inc.

 

Former Name if Applicable: ____________________________________________________________

 

Address of Principal Executive Office (Street and Number):

 

8880 Rio San Diego Drive

Suite 800

San Diego, CA 92108

 

 

 

 

 

 

PART II - RULE 12B-25(B) AND (C)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

 

[X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
[X] (b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III – NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 cannot be filed within the prescribed time period because the Registrant is experiencing unexpected delays in the collection and compilation of certain information required to be included in the Form 10-K. The Registrant’s Annual Report on Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date.

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification:

 

  Jolie Kahn   011-972   215-375-6646
  (Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).

 

[X] Yes [  ] No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

[  ] Yes [X] No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

2
 

 

Sigyn Therapeutics, Inc.

(Name of Registrant as specified in charter)

 

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: March 31, 2021 By: /s/ Jim Joyce
  Name: Jim Joyce
  Title: Chief Executive Officer

 

3

 

Sigyn Therapeutics (QB) (USOTC:SIGY)
Gráfica de Acción Histórica
De Feb 2025 a Mar 2025 Haga Click aquí para más Gráficas Sigyn Therapeutics (QB).
Sigyn Therapeutics (QB) (USOTC:SIGY)
Gráfica de Acción Histórica
De Mar 2024 a Mar 2025 Haga Click aquí para más Gráficas Sigyn Therapeutics (QB).